Brief: Oncolytics Biotech Reports $29.7 Million In Cash, Cash Equivalents, Marketable Securities As Of March 31, Provides Projected Cash Runway For At Least 12 Months
05/05/2023 12:39
May 5 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH - $29.7 MILLION IN CASH, CASH
EQUIVALENTS,
MARKETABLE SECURITIES AS OF MARCH 31, PROVIDES PROJECTED CASH
RUNWAY FOR AT LEAST 12 MONTHS
* ONCOLYTICS BIOTECH INC QTRLY BASIC AND DILUTED LOSS PER
COMMON
SHARE $0.10
Source text for Eikon: ID:nCNWd1Zhja
Further company coverage: ONC.TO
((Reuters.Brief@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer